Advances in Sarcopenia: Mechanisms, Therapeutic Targets, and Intervention Strategies

Overview

Journal Arch Pharm Res

Specialty Pharmacology

Date 2024 Apr 9

PMID 38592582

Authors

Youle Zheng

Jin Feng

Yixin Yu

Min Ling

Xu Wang

Affiliations

Soon will be listed here.

Abstract

Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in managing sarcopenia. However, it is important to consider the variable efficacy and potential side effects associated with these treatments. There are currently no drugs approved by the Food and Drug Administration for sarcopenia. The ongoing research aims to develop more effective strategies in the future. Our review of research on disease mechanisms and drug development will be a valuable contribution to future research endeavors.

Citing Articles

Sarcopenia and frailty among older Chinese adults: Findings from the CHARLS study.

Xu W, Cai J, Liu Y, Li L, Ye X, Wang P PLoS One. 2024; 19(11):e0312879.

PMID: 39509449 PMC: 11542859. DOI: 10.1371/journal.pone.0312879.

Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview.

Najm A, Moldoveanu E, Niculescu A, Grumezescu A, Beuran M, Gaspar B Int J Mol Sci. 2024; 25(19).

PMID: 39409095 PMC: 11476378. DOI: 10.3390/ijms251910766.

Dietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD).

Soliman A, Hegazy M, Ahmed R, Abdelghaffar S, Gomaa M, Alwakil S J Health Popul Nutr. 2024; 43(1):139.

PMID: 39227957 PMC: 11373442. DOI: 10.1186/s41043-024-00619-y.

Sonographic Features of Rectus Femoris Muscle in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Their Correlation with Body Composition Parameters and Muscle Strength: Results of a Single-Center Cross-Sectional Study.

Sheptulina A, Yafarova A, Mamutova E, Drapkina O Biomedicines. 2024; 12(8).

PMID: 39200149 PMC: 11351426. DOI: 10.3390/biomedicines12081684.

Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets.

Ali S, Nkembo A, Tipparaju S, Ashraf M, Xuan W Can J Physiol Pharmacol. 2024; 102(12):697-708.

PMID: 39186818 PMC: 11663012. DOI: 10.1139/cjpp-2024-0201.

References

Abe S, Ezaki O, Suzuki M . Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial. J Nutr. 2016; 146(5):1017-26. DOI: 10.3945/jn.115.228965. View

Adams V, Bowen T, Werner S, Barthel P, Amberger C, Konzer A . Small-molecule-mediated chemical knock-down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure. J Cachexia Sarcopenia Muscle. 2019; 10(5):1102-1115. PMC: 6818456. DOI: 10.1002/jcsm.12448. View

Adams V, Gussen V, Zozulya S, Cruz A, Moriscot A, Linke A . Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy. Cells. 2020; 9(10). PMC: 7600862. DOI: 10.3390/cells9102272. View

Agapova O, Fang Y, Sugatani T, Seifert M, Hruska K . Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int. 2016; 89(6):1231-43. PMC: 4868771. DOI: 10.1016/j.kint.2016.02.002. View

Alway S, Mohamed J, Myers M . Mitochondria Initiate and Regulate Sarcopenia. Exerc Sport Sci Rev. 2017; 45(2):58-69. PMC: 5357179. DOI: 10.1249/JES.0000000000000101. View

Amorim J, Coppotelli G, Rolo A, Palmeira C, Ross J, Sinclair D . Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol. 2022; 18(4):243-258. PMC: 9059418. DOI: 10.1038/s41574-021-00626-7. View

Anker S, Morley J, von Haehling S . Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016; 7(5):512-514. PMC: 5114626. DOI: 10.1002/jcsm.12147. View

Azzout-Marniche D . New Insight into the Understanding of Muscle Glycolysis: Sestrins, Key Pivotal Proteins Integrating Glucose and Leucine to Control mTOR Activation. J Nutr. 2023; 153(4):915-916. DOI: 10.1016/j.tjnut.2023.01.029. View

Bagherniya M, Mahdavi A, Shokri-Mashhadi N, Banach M, von Haehling S, Johnston T . The beneficial therapeutic effects of plant-derived natural products for the treatment of sarcopenia. J Cachexia Sarcopenia Muscle. 2022; 13(6):2772-2790. PMC: 9745475. DOI: 10.1002/jcsm.13057. View

10.

Barone B, Napolitano L, Abate M, Cirillo L, Reccia P, Passaro F . The Role of Testosterone in the Elderly: What Do We Know?. Int J Mol Sci. 2022; 23(7). PMC: 8998588. DOI: 10.3390/ijms23073535. View

11.

Bauer J, Verlaan S, Bautmans I, Brandt K, Donini L, Maggio M . Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015; 16(9):740-7. DOI: 10.1016/j.jamda.2015.05.021. View

12.

Becker C, Lord S, Studenski S, Warden S, Fielding R, Recknor C . Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015; 3(12):948-57. DOI: 10.1016/S2213-8587(15)00298-3. View

13.

Bellanti F, Lo Buglio A, Vendemiale G . Muscle Delivery of Mitochondria-Targeted Drugs for the Treatment of Sarcopenia: Rationale and Perspectives. Pharmaceutics. 2022; 14(12). PMC: 9782427. DOI: 10.3390/pharmaceutics14122588. View

14.

Bennett J, Pratt A, Dodds R, Sayer A, Isaacs J . Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol. 2023; 19(4):239-251. DOI: 10.1038/s41584-023-00921-9. View

15.

Birkbeck M, Blamire A, Whittaker R, Sayer A, Dodds R . The role of novel motor unit magnetic resonance imaging to investigate motor unit activity in ageing skeletal muscle. J Cachexia Sarcopenia Muscle. 2020; 12(1):17-29. PMC: 7890268. DOI: 10.1002/jcsm.12655. View

16.

Blasco A, Gras S, Modol-Caballero G, Tarabal O, Casanovas A, Piedrafita L . Motoneuron deafferentation and gliosis occur in association with neuromuscular regressive changes during ageing in mice. J Cachexia Sarcopenia Muscle. 2020; 11(6):1628-1660. PMC: 7749545. DOI: 10.1002/jcsm.12599. View

17.

Bogdanovich S, Krag T, Barton E, Morris L, Whittemore L, Ahima R . Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002; 420(6914):418-21. DOI: 10.1038/nature01154. View

18.

Bondesen B, Mills S, Kegley K, Pavlath G . The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol. 2004; 287(2):C475-83. DOI: 10.1152/ajpcell.00088.2004. View

19.

Campbell W, Crim M, Dallal G, Young V, Evans W . Increased protein requirements in elderly people: new data and retrospective reassessments. Am J Clin Nutr. 1994; 60(4):501-9. DOI: 10.1093/ajcn/60.4.501. View

20.

Cannavino J, Brocca L, Sandri M, Grassi B, Bottinelli R, Pellegrino M . The role of alterations in mitochondrial dynamics and PGC-1α over-expression in fast muscle atrophy following hindlimb unloading. J Physiol. 2015; 593(8):1981-95. PMC: 4405755. DOI: 10.1113/jphysiol.2014.286740. View